Measuring symptoms as a critical component of drug development and evaluation in hematological diseases

Author： Williams Loretta A   Yucel Emre   Cortes Jorge E   Cleeland Charles S  

Publisher： Future Science

ISSN： 2041-6792

Source： Clinical Investigation, Vol.3, Iss.12, 2013-12, pp. : 1127-1138

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Therapeutic Drug Monitoring as a Component of Personalized Medicine: Applications in Pediatric Drug Development

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 95, Iss. 2, 2014-02 ,pp. : 138-140

John Wiley & Sons Inc

Access to resources Recommend Favorite

A Critical Evaluation of the Clinical Evidence for Pomegranate Preparations in the Prevention and Treatment of Cardiovascular Diseases

By  

PHYTOTHERAPY RESEARCH, Vol. 29, Iss. 4, 2015-04 ,pp. : 501-508

John Wiley & Sons Inc

Access to resources Recommend Favorite

Development and psychometric evaluation of the Quality of Patient‐Centered Cancer Care measure with hematological cancer survivors

By  

CANCER, Vol. 121, Iss. 14, 2015-07 ,pp. : 2383-2392

John Wiley & Sons Inc

Access to resources Recommend Favorite

Midkine: an emerging target of drug development for treatment of multiple diseases

By  

BRITISH JOURNAL OF PHARMACOLOGY (ELECTRONIC), Vol. 171, Iss. 4, 2014-02 ,pp. : 811-813

John Wiley & Sons Inc

Access to resources Recommend Favorite

Catalyzing the critical path initiative: FDA's progress in drug development activities

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 97, Iss. 3, 2015-03 ,pp. : 221-233

John Wiley & Sons Inc

Access to resources Recommend Favorite